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MULLINS ET AL. 429Epidemiological studies have recognized a genetic diathesis for
suicidal behavior, which is independent of other psychiatric
disorders. Genome-wide association studies (GWAS) on suicide
attempt (SA) and ideation have failed to identify specific genetic
variants. Here, we conduct further GWAS and for the first time,
use polygenic score analysis in cohorts of patients with mood
disorders, to test for common genetic variants for mood disor-
ders and suicide phenotypes. Genome-wide studies for SA were
conducted in the RADIANT and GSK-Munich recurrent depres-
sion samples and London Bipolar Affective Disorder Case-Con-
trol Study (BACCs) thenmeta-analysis was performed. A GWAS
on suicidal ideation during antidepressant treatment had previ-
ously been conducted in the Genome Based Therapeutic Drugs
for Depression (GENDEP) study. We derived polygenic scores
from each sample and tested their ability to predict SA in the
mood disorder cohorts or ideation status in the GENDEP study.
Polygenic scores for major depressive disorder, bipolar disorder
and schizophrenia from the Psychiatric Genomics Consortium
were used to investigate pleiotropy between psychiatric disor-
ders and suicide phenotypes. No significant evidence for associ-
ation was detected at any SNP in GWAS or meta-analysis.
Polygenic scores for major depressive disorder significantly
predicted suicidal ideation in the GENDEP pharmacogenetics
study and also predicted SA in a combined validation dataset.
Polygenic scores for SA showed no predictive ability for suicidal
ideation. Polygenic score analysis suggests pleiotropy between
psychiatric disorders and suicidal ideationwhereas the tendency
to act on such thoughtsmay have a partially independent genetic
diathesis.  2014 The Authors. American Journal of Medical Genetics Part B:
Neuropsychiatric Genetics published by Wiley Periodicals, Inc.
Key words: pleiotropy; meta-analysis; prediction; associationINTRODUCTION
Suicide is one of the ten leading causes of death and rates of suicide
are far exceeded by suicide attempts, which occur up to 20 times
more frequently [World Health Organisation, 2005; Lim
et al., 2012]. Over 90% of suicide attempters or victims have a
psychiatric diagnosis, particularly major depression and bipolar
disorder [Beautrais et al., 1996; Qin, 2011]. However, twin, family
and adoption studies have recognized a genetic component to
suicidal behavior, which is independent of other psychiatric dis-
orders [Schulsinger et al., 1979; Brent et al., 1996; Roy and
Segal, 2001]. This supports a stress-diathesis model whereby psy-
chiatric illnesses or other life stressors are not exclusively responsi-
ble for suicide attempts (SA) but rather that they may aggravate an
individual’s genetic predisposition to suicidal behavior [Mann
et al., 1999].
Candidate gene association studies on suicidal behavior have
yielded either inconsistent or negative results. Similarly, genome-
wide association studies (GWAS) performed to date have failed to
identify associations at the genome-wide significance level [Perlis
et al., 2010; Schosser et al., 2011; Willour et al., 2012; Galfalvy
et al., 2013]. Other genetic studies have focused on treatmentemergent or treatment worsening suicidal ideation (SI) in patients
taking antidepressant drugs [Laje et al., 2009; Perroud et al., 2012].
One model for suicidal behavior is as a complex trait, which
occurs when the joint effect of many risk and protective genetic
variants, together with an environmental contribution, crosses a
certain liability threshold. GWAS captures alleles that are common
in the population and are each likely to have a very small effect on a
complex phenotype [Wray et al., 2007]. Simultaneously investigat-
ing thousands of SNPs, which individually do not reach statistical
significance, could explain a greater amount of the heritability.
Polygenic score analysis uses ensembles of SNPs from a GWAS in a
discovery sample, weighted by their log odds ratios to create a score
across all these alleles for each individual in an independent
validation sample [Dudbridge, 2013]. The polygenic score can
then be tested for its ability to predict case and control status in
the validation dataset or to predict a different phenotype in the
validation dataset, to investigate pleiotropy between traits [Purcell
et al., 2009].
Suicidal behavior and ideation have been associated with most
psychiatric and behavioral disorders. Pleiotropic genetic effects
have been identified between several disorders which have shared
symptoms or are commonly comorbid, using polygenic scores for
one disorder to predict another [Purcell et al., 2009].
GWAS on suicide attempt in patients with mood disorders may
detect genetic variants predisposing to SAwhich are independent of
psychiatric disorders and a meta-analysis may identify novel asso-
ciations and reduce false positive results. Polygenic score analysis
could explain a larger component of the heritability of suicidal
behavior, thanwould individual alleles with small effect sizes. There
may be pleiotropic genetic effects between suicide attempt or
ideation and depression, schizophrenia or bipolar disorder, since
suicidality is a common comorbidity in these illnesses.
In this article, we test for genetic associations with suicide
attempt and suicidal ideation in four studies of depression and
bipolar disorder. Using these, and results from the Psychiatric
Genomics Consortium, we construct polygenic scores and test
their predictive ability for suicide attempt and ideation.
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Clinical Sample Collection
A GWAS on SA has previously been conducted in the RADIANT
sample (n¼ 2,023) of patients with recurrent major depressive
disorder [Schosser et al., 2011]. Briefly, patients were diagnosed
using the Schedules for Clinical Assessment in Neuropsychiatry
Interview (SCAN), according to standardised criteria in the
International Classification of Diseases 10th edition (ICD-10)
or Diagnostic and Statistical Manual 4th edition (DSM-IV)
[World Health Organisation, 1998; Wing et al., 1990; American
Psychiatric Association, 2000]. The SCAN was used to record
information on patients’ worst and second worst episodes of
depression including suicidal behavior. Exclusion criteria
have been described previously and include Axis I diagnoses
other than anxiety disorder [Farmer et al., 2004; Cohen-Woods
et al., 2009].
The GSK-Munich recurrent depression cohort (n¼ 807) was
recruited at the Max-Planck Institute of Psychiatry, Germany
according to the same protocol [Muglia et al., 2010].
Participants in the Bipolar Affective Disorder Case Control
Study (BACCs) (n¼ 470) were recruited in London, United King-
dom in the samemanner and assessed for diagnosis using the SCAN
interview and Operational Criteria Checklist for Psychotic Illness
Program [McGuffin et al., 1991]. Exclusion criteria have been
described previously [Gaysina et al., 2009].
A GWAS on treatment-emergent and treatment-worsening
suicidal ideation has also been reported in the Genome Based
Therapeutic Drugs for Depression Study (GENDEP), comprised
of patients with major depression on a 12 week antidepressant
treatment with either escitalopram—a selective serotonin reuptake
inhibiter or nortriptyline—a tricylic antidepressant [Uher et al.,
2010; Perroud et al., 2012].
Participants in all studies were of European ancestry. Whole
blood samples were collected in ethylene-diamine-tetra-acetic acid
(EDTA) for genetic analysis.Phenotype Definitions
Suicide attempt was defined using a question on the SCAN
interview, as self-injury or suicide attempt resulting in serious
harm, or an attempt at suicide designed to result in death
[Schosser et al., 2011]. Evidence collected retrospectively for
the worst and second worst depressive episode was used in this
study.
In the GENDEP study, participants were evaluated weekly using
the 17-item Hamilton Rating Scale for Depression, the self-report
Beck Depression Inventory and the Montgomery-Asberg Depres-
sion Rating Scale, which each include a question on suicidal
ideation [Hamilton, 1960; Beck et al., 1961; Montgomery and
Asberg, 1979]. A composite score was used to define suicidal
ideation at baseline, treatment emergent (TESI) and treatment
worsening suicidal ideation (TWOSI) [Perroud et al., 2009]. Indi-
viduals with either TWOSI or TESI were considered as cases and
those with no suicidal ideation or baseline ideation which did not
worsen during treatment were used as controls.Genotyping
DNA was extracted from blood samples and those of sufficient
quantity and quality were genotyped [Freeman et al., 2003]. GSK-
Munich and BACCs samples were genotyped on Illumina Human-
Hap550-Quadþ BeadChipmicroarrays (Illumina, Inc., San Diego,
CA). RADIANT and GENDEP samples were genotyped on Illu-
mina Human610-Quad BeadChip (Illumina, Inc.) by the Centre
National de Ge´notypage (Evry Cedex, France).
Statistical Analysis
Standard quality control procedures were implemented in all
studies to clean the data and control for population stratification
[Lewis et al., 2010; Schosser et al., 2011; Perroud et al., 2012].
GWAS on SA were performed by logistic regression using the
whole genome analysis toolset PLINK 1.07 (http://pngu.mgh.har-
vard.edu/purcell/plink/) [Purcell et al., 2007] in the GSK-Munich
and BACCs samples and have previously been reported in RADI-
ANT[Schosser et al., 2011].AGWASonTESI/TWOSIhas alsobeen
reported in GENDEP [Perroud et al., 2012]. To account for
multiple testing, genome wide significance was ascribed at P< 5
 108 and findings of suggestive significance at P< 5 106
[Dudbridge and Gusnanto, 2008]. Principal components were
included as covariates to account for population stratification
and the median chi-squared test statistic (l) was used to test the
quality of control [Devlin et al., 2001]. This was close to 1 in all
studies (Supplementary material), suggesting no inflation of test
statistics and so the unadjusted P values were reported.
A fixed effects meta-analysis on SA was performed between the
RADIANT, GSK-Munich, and BACCs studies, using inverse vari-
ance weighting to combine the results [Evangelou and Ioannidis,
2013].
Assuming a discrete trait Case–Control model, the Genetic
Power Calculator [Purcell et al., 2003] was used to determine
the power to detect association at both significance levels, for
the individual studies andmeta-analysis (Supplementarymaterial).
TheGWASresults fromthese fourdiscovery studieswerepruned
for linkage disequilibrium (LD) using theP-value informed clump-
ing method in PLINK. This preferentially retains SNPs with the
strongest evidence of association and removes SNPs in LD that
showweaker evidence of association. Subsets of SNPs were selected
from the results at 5 increasingly liberal P value thresholds
(P< 0.01,P< 0.05,P< 0.1,P< 0.3,P< 0.5). Sets of alleles, weight-
ed by their original log odds ratios (OR) in the GWAS, were
summarized into a polygenic score for each individual in the
different validation datasets using PLINK. The polygenic score
was tested for ability to predict SAor TWOSI/TESI in the validation
sample using logistic regression, with principal components as
required, to calculate Nagelkerke’s pseudo-R2, a measure of the
variance explained [Nagelkerke, 1991].
The same procedures were followed using GWAS summary results
from the Psychiatric Genomics Consortium available online (https://
pgc.unc.edu/). Polygenic scores for major depressive disorder (PGC-
MDD), bipolar disorder (PGC-BIP) and schizophrenia (PGC-SCZ)
were tested for ability to predict SAor TWOSI/TESI in each of the four
validation samples [Psychiatric GWAS Consortium Bipolar Disorder
MULLINS ET AL. 431Working Group, 2011; Schizophrenia Psychiatric Genome-Wide As-
sociation Study (GWAS) Consortium, 2011]. In the case of PGC-
MDD, published results were from a mega-analysis of nine studies,
which included the RADIANT and GSK-Munich samples [Major
Depressive Disorder Working Group of the Psychiatric Genomics
Consortium, 2013]. Meta-analyses were repeated using summary
results from the individual studies and excluding the RADIANT or
GSK-Munich sample as required, avoiding overlap between discovery
and validationdatasets,which could cause false positive results. Finally,
theRADIANT,GSK-Munich andBACCsdatasetswere also combined
into one larger validation sample and polygenic scores for psychiatric
disorders from the PGC studies inMDD, SCZ, and BIP were tested as
predictors of SA. Statistical analysis was performed using R 3.0.0.
A literature review was performed using Pubmed http://www.ncbi.
nlm.nih.gov/pubmed/ to investigate genes previously associated with
suicidal ideation, suicide attempt or related endophenotypes for a
candidate association study. All genotyped SNPs within the selected
candidate genes were extracted from the meta-analysis results. SNPs
were pruned for LD by P value informed clumping and the threshold
for significance was calculated using a Bonferroni correction for the
number of SNPs tested (Supplementary material).Ethical Approval
All patients gave written informed consent to take part in these
studies. Data were anonymized with a research identification
number only. Ethical approval was obtained from the Ethics
Committee at the Institute of Psychiatry, King’s College London
or the local ethics committee at each center of recruitment.RESULTS
Sample Characteristics
Sample characteristics are shown inTable I. A similar proportion of
cases in RADIANT, GSK-Munich, and BACCs studies were suicide
attempters (12–16%), while rates of TESI/TWOSI in the GENDEP
study were higher (32%).Genome-Wide Association Analysis
No SNP reached genome-wide significance in the GWAS on SA in
GSK-Munich and BACCs (Supplementarymaterial). rs9351947 onTABLE I. Sample
Sample No. individuals
No. SA or TESI/TWOSI
cases (%)
RADIANTa 2,023 251 (12.4%)
GSK-Municha 807 106 (13.1%)
BACCsa 440 69 (15.7%)
Meta-analysisb 3,270 426 (13.0%)
GENDEPc 747 237 (31.7%)
aCases are suicide attempters.
bRADIANT, GSK-Munich, and BACCs studies.
cCases in the GENDEP study are those with suicidal ideation.chromosome 6 reached suggestive significance in the GSK-Munich
analysis, whereas the BACCs sample was underpowered to detect
sucheffects (power calculations shown inSupplementarymaterial).
The fixed effects meta-analysis performed between the RADI-
ANT, GSK-Munich and BACCs studies on SA, had much higher
power to detect association (87% power at the suggestive signifi-
cance level for a minor allele with a frequency of 0.2 and OR¼ 1.5
and 57% power at genome-wide significance). No SNP reached
genome-wide significance (Table II). SNPs on chromosomes 7, 4
and 11 reached suggestive significance, and had not reached this
threshold in the individual study analysis (Fig. 1).Meta-analysis did
not provide any further support for any of the SNPs of suggestive
significance in the individual studies (Supplementary material).
Candidate Association Study
From the meta-analysis, a candidate association study of 19 genes
previously associated with suicide was also performed though no
SNPs were significant after a Bonferroni correction was applied
(Supplementary material). A SNP in ABI3BP had reached GWAS
significance in a previous study of SA in depression, however the
finding did not replicate in this analysis [Perlis et al., 2010].Polygenic Score Analysis
SNPs from four discovery GWAS on suicide attempt (RADIANT,
GSK-Munich, BACCs), one study on suicidal ideation (GENDEP)
and three studies on psychiatric disorders (PGC-MDD, PGC-BIP,
PGC-SCZ) were used to derive polygenic scores for each individual
in four validation datasets (RADIANT, GSK-Munich, BACCs,
GENDEP). Subsets of SNPs were selected according to increasingly
liberal P value thresholds (PT) in the discovery phase GWAS
analysis. Scores were tested for their ability to predict suicide
attempt or ideation in the validation samples by calculating Nagel-
kerke’s pseudo R2, a measure of the variance explained (Fig. 2).
In theRADIANTvalidation sample, only polygenic scores forTESI/
TWOSI derived from GENDEP showed significant predictive ability
for suicide attempt (P¼ 0.021) (Fig. 2). The Nagelkerke R2 was 0.005
indicating that0.5%ofvariance in thephenotypecouldbeexplainedby
SNPs within PT< 0.01 of the GENDEP polygenic score, with no
significant prediction obtained at other P value thresholds.
In the GSK-Munich validation dataset, none of the polygenic






1,477 (73.0%) 22.7 (11.5) 46.2 (12.0)
531 (65.8%) 35.8 (14.1) 51.1 (13.8)
294 (66.8%) 21.7 (8.4) 47.7 (11.5)
2,302 (70.4%) 26.0 (13.3) 47.6 (12.5)






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































432 AMERICAN JOURNAL OF MEDICAL GENETICS PART B< 0.3 and PT< 0.5 scores for SA from the GSK-Munich sample had
predictive ability for SA in BACCs (R2¼ 1.6%, P¼ 0.04).
Polygenic scores for major depressive disorder from the PGC
were significant predictors of TESI/TWOSI in the GENDEP vali-
dation dataset (Fig. 2), accounting for 1%of TESI/TWOSI variance
(PT< 0.3, P¼ 0.015). Scores for schizophrenia also showed signifi-
cant predictive ability in GENDEP, but were lower in cases
experiencing TESI/TWOSI than controls with no ideation. Poly-
genic scores for SA showednopredictive ability for suicidal ideation
during antidepressant treatment in GENDEP (Fig. 2).
The RADIANT, GSK-Munich, and BACCs validation datasets
were merged into a single dataset in order to increase the precision
of prediction. This sample has the same characteristics as themeta-
analysis (n¼ 3,270) and includes 426 SA cases. Scores for MDD,
BIP and SCZ from the PGC were tested as predictors of SA in this
combined validation dataset (Supplementary material). PGC-
MDD scores showed significant predictive ability for SA, the largest
R2 being 0.3% at PT< 0.3 (P¼ 0.013). Scores from PGC-SCZ also
showed significant prediction (R2¼ 0.2% at PT< 0.05, P¼ 0.05),
but the score was lower in SA cases than in non-SA cases, consistent
with the previous analysis in the GENDEP sample.DISCUSSION
Meta-analysis of the RADIANT, GSK-Munich, and BACCs studies
found no genome-wide significant SNPs associated with SA
(Table II), in commonwithmost previous genome-wideassociation
studies on suicide attempt. This probably reflects the limited power
of our sample to detect the genetic contribution to a complex trait
like SA inpatientswithmooddisorders.A similar challenge is seen in
detecting genetic associations with the underlying mood disorders,
where the PGC-MDD study detected no significant loci despite
using a sample of over 9,000 cases and 9,000 controls [Major
Depressive Disorder Working Group of the Psychiatric Genomics
Consortium, 2013].
The GENDEP study was excluded from the meta-analysis be-
cause of the different phenotype assessed (suicidal ideation, not
suicide attempt), and its design (a prospective study during a 12-
week treatment period rather than a retrospective study). There is
considerable evidence in the literature that suicidal ideation is not
part of the same phenotypic spectrum as SA. An excess of suicidal
ideation was found in the relatives of suicide victims but was not
significant after adjustment for psychiatric disorders [Brent
et al., 1996]. It has been proposed that ideation co-segregates
with psychiatric disorders, whereas the tendency to act upon
such thoughts has a partially separate genetic diathesis [Mann
et al., 1999]. This suggests that suicidal ideation should be excluded
from molecular genetic studies on SA.
A SNP inRARRES2was themost significant finding in themeta-
analysis (Table II). This gene encodes a retinoic acid receptor
responder. Retinoic acid is a signaling molecule involved in neuro-
genesis and has been linked to depression and suicide [O’Reilly
et al., 2006; Siegenthaler et al., 2009]. Previous GWAS and linkage
studies on SA in different psychiatric disorders and meta-analysis
between them, have implicated the 2p12 region [Hesselbrock
et al., 2004; Willour et al., 2007; Willour et al., 2012; Butler
et al., 2010]. Further support is obtained in this meta-analysis
FIG. 1. Manhattan plot of meta-analysis between RADIANT, GSK-Munich, and BACCs samples.
MULLINS ET AL. 433from rs17010519 in theHK2 gene (P¼ 1.15 105)which iswithin
the linkage region previously identified.
Although genome-wide association studies have low power to
detect association at a single SNP in psychiatric phenotypes,
polygenic score analysis provides an alternative approach, simul-
taneously testing ensembles of markers, which may not reach
significance individually. This approach has been used by the
Psychiatric Genomics Consortium and the International Schizo-
phrenia Consortium to investigate major depression and schizo-
phrenia [Purcell et al., 2009; Major Depressive Disorder Working
Group of the Psychiatric Genomics Consortium, 2013].
Polygenic scores for SA (RADIANT,GSK-Munich, andBACCs),
suicidal ideation (GENDEP) and depression, bipolar disorder and
schizophrenia from the PGC, were tested for their ability to predict
suicide attempt or ideation in four validation datasets. Some
significant predictive ability was found using GENDEP scores
for suicidal ideation to predict SA in the RADIANT validation
dataset (Fig. 2). The highestR2 in our analysis was 1.6%using scores
for SA from GSK-Munich to predict SA in the BACCs sample
(Fig. 2), which is modest but is in line with previous results using
polygenic scores for depression and schizophrenia, as predictors in
independent samples, 0.6% and 3% respectively [Purcell
et al., 2009; Major Depressive Disorder Working Group of the
Psychiatric Genomics Consortium, 2013].
This is the first study to use polygenic score analysis on studies of
suicide attempt and suicidal ideation, although lack of power is still a
limitation, given the moderate sample size of most of the discovery
data sets (RADIANT, GSK-Munich, BACCs, and GENDEP)
[Dudbridge, 2013]. The size of the validation dataset determines
the precision with which the phenotype can be predicted
[Dudbridge, 2013]. Validation datasets used here may be too small
and this could explain why the majority of polygenic scores did not
yield significant P values. Suicide attempt has a heritability of 55%, so
if the polygenic score explained half of the heritability of liability, asample of many thousands of individuals would still be required to
achieve apredictive ability of 75%,which is the standard for screening
at risk populations [Voracek and Loibl, 2007; Dudbridge, 2013].
Polygenic scores for MDD, BIP and SCZ from the Psychiatric
GenomicsConsortiumwere tested for predictionof SA and suicidal
ideation, to investigate possible pleiotropy between these common-
ly comorbid conditions.
Polygenic scores for psychiatric disorders showed no significant
prediction of SA in any of the validation datasets individually
(Fig. 2), but scores for MDD did predict SA in the RADIANT,
GSK-Munich, and BACCs validation datasets combined (Supple-
mentary material). The limitation of sample size in the discovery
phase also applies to theMDDstudyby thePGCandmay reduce the
accuracy of this polygenic score [MajorDepressiveDisorderWork-
ing Group of the Psychiatric Genomics Consortium, 2013]. How-
ever, combining the validation datasets appears to have allowed
more precise prediction which reached statistical significance.
Scores for bipolar disorder showed no predictive ability in the
combined validation sample, which may be due to the small
number of patients with BIP included.
There has been much debate surrounding the relationship
between psychiatric disorders and suicide attempt. Many epidemi-
ological studies have shown that suicide and suicide attempt
aggregates in families even after controlling for the presence of
psychiatric disorders [Brent et al., 1996; Johnson et al., 1998]. Two
pedigrees were reported with equal loading for mood disorder, one
of which was also loaded for suicide while the other had not a single
case of suicide [Egeland and Sussex, 1985]. It has been suggested
that the familial transmission of suicide attempt is conditional on
but independent of mood disorders [Turecki, 2001]. The results
presented here are consistent with a partial pleiotropy between
major depression and SA.
Polygenic scores for major depressive disorder significantly
predicted suicidal ideation in theGENDEPpharmacogenetic study,
FIG. 2. Polygenic scores for suicide attempt, suicidal ideation, and psychiatric disorders from seven discovery datasets used to predict suicide
attempt in the RADIANT, GSK-Munich, and BACCs validation datasets and suicidal ideation in GENDEP. The y-axis indicates Nagelkerke’s pseudo
R2, a measure of the variance explained and the x-axis indicates the discovery datasets from which the polygenic scores were derived. The
five P-value thresholds used (PT< 0.01, PT< 0.05, PT< 0.10, PT< 0.30, PT< 0.50) to select SNPs are plotted left to right for each discovery
dataset. Stars indicate polygenic scores with significant predictive ability (P< 0.05).
434 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bsuggesting a pleiotropy between liability to depression and TESI/
TWOSI (Fig. 2). In contrast, polygenic scores reflecting liability to
bipolar disorder did not predict TESI/TWOSI during antidepres-
sant treatment (Fig. 2). These findings suggest that emergence or
worsening of suicidal thoughts during treatment with antidepres-
sants is a phenomenon inherent to the genetic liability todepression
and is not a reflection of latent or misdiagnosed bipolar disorder
[Tansey et al., 2014], as was previously suggested [Berk and
Dodd, 2005; Seemuller et al., 2009]. Scores for suicide attempt
did not predict TESI/TWOSI in GENDEP, further emphasizing the
distinct genetic aetiology of suicidal ideation and suicidal behavior.
It is important to note that TESI/TWOSI occurs in a minority of
patients on drug treatment. It is unclear whether the aetiology of
suicidal ideation lies in the mechanism of action of the antidepres-
sant drug, a genetic susceptibility in the patient or even amixture of
both in a gene-by-drug interaction [Perroud et al., 2012]. Our
results suggest that it is an inherent part of the genetic liability to
depressive illness.Since suicidal behavior is a spectrum of severity with heteroge-
neous genetic architecture, its decomposition by sex, age, number,
or violence of attempts could lead to increased homogeneity, but
much larger sample sizes would be required for these analyses.
Furthermore, an integrative approach, incorporating genetic, epi-
genetic and environmental effects may be necessary to realistically
capture the multifactorial nature of SA.
Molecular genetic studies on suicide attempt may contribute to
the development of a biomarker riskmodel to be used alongside the
clinical riskmodel of current practice in order to target intervention
strategies to psychiatric patients at increased risk. Increased insight
into the pathophysiology of suicidal behavior could also identify
novel therapeutic targets.
In conclusion, the genetic architectureof SAand ideation is likely
to be highly polygenic, with risk variants of small effect sizes which
these GWAS studies were underpowered to detect, in a SNP-by-
SNP analysis. Using polygenic scores as predictors in independent
datasets is a more appropriate approach. Polygenic scores indicate
MULLINS ET AL. 435that SA and ideation are unlikely to be different severities of the
same spectrum.Agenetic susceptibility to suicidal ideation couldbe
part of the genetic aetiology of psychiatric disorders, while in
contrast there is likely to be some independent genetic effects,
which predispose to suicide attempt.ACKNOWLEDGMENTS
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